Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
AIRCULES
Asthma Phase II
- 6.8 weeks
- 2nd site activated in Canada
Airlympus
Asthma Phase II
- 6.6 weeks
- Canadian FPI - 3rd patient enrolled globally
Airlympus
Asthma Phase II
- 6.8 weeks
B-Focus
HIV / Hepatitis B Phase II
- 8.8 weeks
- 1st site activated (ex æquo) in Canada, 3rd site activated (ex æquo) worldwide, Canadian FPI
B-Focus
HIV / Hepatitis B Phase II
- 8 weeks
- 3rd site activated (ex æquo) in Canada
B-United (218309)
Chronic Hepatitis B Phase II
- 9 weeks
- 1st site activated in Canada and Canadian FPI
C1071032
Multiple Myeloma Phase III
- 14.8 weeks
- 1st site activated in Canada
CA231-0000
Advanced Malignant Tumors Phase I/Ib
- 7.2 weeks
- 1st site activated in Canada and Canadian FPI
CA233-0000
Advanced Solid Tumors Phase I
- 13.4 weeks
- 1st site activated in Canada
CA235-0001
Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase I
- 8.6 weeks
- 1st site activated in Canada and 2nd site activated worldwide
CFXX489A12101
Pancreatic, Lung, Breast and Colorectal Cancers Phase I
- 7.2 weeks
- 1st site activated in Canada and 2nd site activated worldwide
CFXX489A12101
Pancreatic, Lung, Breast and Colorectal Cancers Phase I
- 9.2 weeks
- 2nd site activated in Canada
CVAY736A2202
Autoimmune Disease Phase II
- 8.2 weeks
CYTB323R12101
Progressive Multiple Sclerosis (PMS) Phase I/II
- 11.8 weeks
- 1st site activated in Canada, 2nd site activated worldwide, Canada FPI and 3rd patient enrolled worldwide
DRI17476 (Fabulinus)
Type 1 Diabetes Phase II
- 12.4 weeks
- 3rd site activated worldwide
DRI17476 (Fabulinus)
Type 1 Diabetes Phase II
- 10.2 weeks